Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

205
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
205
Parametric Survival Analysis: Weibull and Exponential Methods01:14

Parametric Survival Analysis: Weibull and Exponential Methods

683
Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
683
Survival Tree01:19

Survival Tree

172
Survival trees are a non-parametric method used in survival analysis to model the relationship between a set of covariates and the time until an event of interest occurs, often referred to as the "time-to-event" or "survival time." This method is particularly useful when dealing with censored data, where the event has not occurred for some individuals by the end of the study period, or when the exact time of the event is unknown.
 Building a Survival Tree
Constructing a...
172
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

423
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
423
Censoring Survival Data01:09

Censoring Survival Data

267
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
267
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

288
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
288

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

The Effect of Covariate Adjustment for Cox Regression in Cardiovascular Outcome Trials.

Therapeutic innovation & regulatory science·2026
Same author

Antibody Blockade of Ly49/MHC-I interactions enhances Innate and Adaptive Immunity Against Cancer Metastasis.

bioRxiv : the preprint server for biology·2026
Same author

Covariate Adjustment for the Win Odds: Application to Cardiovascular Outcomes Trials.

Statistics in medicine·2026
Same author

Structural mechanism of anti-MHC-I antibody blocking of inhibitory NK cell receptors in tumor immunity.

Communications biology·2026
Same author

Bayesian randomized basket trial design: a case study from the ultra-rare invasive mold infections.

Biometrics·2026
Same author

Knowledge, Practice, and Awareness of Self-Medication among Dental Outpatients: A Cross-Sectional Institutional Study.

Journal of pharmacy & bioallied sciences·2026
Same journal

Understanding the Added Value of Action Limits for QTL Monitoring.

Therapeutic innovation & regulatory science·2026
Same journal

Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?

Therapeutic innovation & regulatory science·2026
Same journal

Validation of the Ontario Protocol Assessment Level (OPAL) Tool for Assessing Clinical Trial Complexity and Supporting Workforce Planning in the Italian Clinical Research Context.

Therapeutic innovation & regulatory science·2026
Same journal

Current Status and Construction Requirements of Drug Clinical Trial Institutions in Sichuan Province in China.

Therapeutic innovation & regulatory science·2026
Same journal

The CARE Program: An Initiative of Patient-Focused Drug Development for Rare Diseases by NMPA.

Therapeutic innovation & regulatory science·2026
See all related articles

Related Experiment Video

Updated: Sep 30, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.4K

The Predictive Individual Effect for Survival Data.

Beat Neuenschwander1, Satrajit Roychoudhury2, Simon Wandel1

  • 1Novartis Pharma AG, Basel, Switzerland.

Therapeutic Innovation & Regulatory Science
|March 16, 2022
PubMed
Summary
This summary is machine-generated.

We introduce the predictive individual effect, a patient-centric measure for quantifying clinical survival benefit in drug development. This approach offers clearer insights than traditional statistics, aiding patient-focused decision-making.

Keywords:
Bayesian predictive inferenceNon-proportional hazardsPatient-centric measureRank preservationSurvival gainTime-to-event endpoint

More Related Videos

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.7K
Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

914

Related Experiment Videos

Last Updated: Sep 30, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.4K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.7K
Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

914

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Pharmacoeconomics

Background:

  • Patient-focused drug development is a key initiative, emphasized by the 21st Century Cures Act and regulatory agencies.
  • Interpretable measures of clinical benefit are crucial for modernizing drug development and healthcare.
  • Cancer trials with time-to-event endpoints require careful consideration, especially when treatment effects vary over time.

Purpose of the Study:

  • To develop a patient-centric measure for quantifying individual clinical survival benefit.
  • To assess the utility of this measure in diverse clinical trial scenarios, including non-proportional hazards.

Main Methods:

  • Introduction of the predictive individual effect, a novel patient-centric measure.
  • Utilizing standard predictive calculations with a rank preservation assumption.
  • Application and evaluation in four recent oncology trials with varied hazard scenarios.

Main Results:

  • The predictive individual effect provides tangible insights into individual patient benefit.
  • Demonstrated utility across scenarios with proportional and non-proportional hazards.
  • Offers added value beyond traditional statistical measures like p-values and hazard ratios.

Conclusions:

  • The predictive individual effect is a direct and interpretable measure of clinical benefit.
  • Facilitates enhanced communication between clinicians, patients, and stakeholders.
  • Recommends its consideration alongside standard statistical results in clinical trials.